D
7607
vs
T
Taiwan Weighted Index
Over the past 12 months, DuoGenic StemCells Corp has underperformed Taiwan Weighted Index, delivering a return of -40% compared to Taiwan Weighted Index's +87% growth.
Stocks Performance
7607 vs Taiwan Weighted Index
Performance Gap
7607 vs Taiwan Weighted Index
Performance By Year
7607 vs Taiwan Weighted Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
DuoGenic StemCells Corp
Glance View
Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. The company is headquartered in Taichung, Taichung and currently employs 25 full-time employees. The company went IPO on 2023-05-25. The culture medium provides the nutrients and raw materials needed for cell growth and reproduction. The cell separator set is used to draw peripheral blood to purify and isolate mononuclear cells. Products include mesenchymal stem cell culture media, endothelial cell culture media, closed cell separation operating devices and others. Products are mainly sold in Taiwan, Asia, and North America.
